Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This first-in-human (FIH) trial aims to establish a safe dose of BNT411 as a monotherapy and
in combination with atezolizumab, carboplatin and etoposide. BNT411 is a toll-like receptor 7
(TLR7) agonist which is expected to mount broad innate and adaptive immune reactions,
especially in combination with cytotoxic therapies and immune checkpoint inhibitors.